What does this research mean for the field?

Switching to the two-drug regimen dolutegravir/lamivudine (DTG/3TC) maintains high rates of virologic suppression and is well-tolerated in a real-world Australian cohort of individuals with HIV. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To identify clinical motivations for switching to a single-tablet dolutegravir/lamivudine regimen and evaluate subsequent 12-month virologic outcomes and discontinuation rates in virologically suppressed individuals with HIV.

August 22, 2026Sexual HealthOpen Access

ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine

View Full Paper

Ask AI

Bookmark

To identify clinical motivations for switching to a single-tablet dolutegravir/lamivudine regimen and evaluate subsequent 12-month virologic outcomes and discontinuation rates in virologically suppressed individuals with HIV.
Retrospective observational study across nine Australian clinics including 276 individuals with HIV and undetectable viral load (<50 copies/mL) who switched to dolutegravir/lamivudine between 1 December 2020 and 1 December 2022.
Provider-completed electronic surveys extracted demographic and medical record data after December 2023 to capture 12-month post-switch follow-up.
The most common pre-switch antiretroviral regimen was abacavir/dolutegravir/lamivudine (54%), and clinician preference for a two-drug regimen was the primary motivation for switching (43%).
Virologic suppression (<50 copies/mL) was maintained by 98% of individuals through 12 months, with zero individuals experiencing virologic failure.
Only one individual (<1%) discontinued dolutegravir/lamivudine during the 12-month follow-up period.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational study reveals high virologic suppression after switching to dolutegravir/lamivudine in people with HIV, indicating two-drug regimens are effective in routine care.

Cite This Study

Eassey et al. (2026) studied this question.

synapsesocial.com/papers/6a895ed9ca7ade938187d020 https://doi.org/10.1071/sh26036

View Full Paper

Ask AI

Bookmark

Implication

Observational study reveals high virologic suppression after switching to dolutegravir/lamivudine in people with HIV, indicating two-drug regimens are effective in routine care.

ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine

Key Points

Discussion

Implication

Cite This Study

ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider